BTK inhibitor Ibrutinib (PCI-32765) treatment can achieve rapid (within days) and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis due to early exiting of CLL cells from lymph nodes534,535. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.